Disruptions likely to persist through 2027, agency says
— Disruptions likely to persist through 2027, agency says
June 16, 2026
• 2 min read
The FDA informed healthcare providers about disruptions in the supply of stereotactic breast biopsy needles that will likely persist through March 2027.
According to the agency, the disruption is expected to impact patient care and "may require adjustments to the clinical management of patients indicated to undergo a breast biopsy."
Hologic aims to bring the needles back on the market by the end of 2026.
Interruptions in the supply of neurosurgical patties, sponges and strips are expected to continue through 2026.
Persistent and prolonged drug shortages across the country are affecting delivery of care across well over 100 therapeutic areas,…
EXCLUSIVE: Patients are being forced to pay privately and even go abroad for vital medicines, including for pancreatic cancer,…
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in…
A new analysis found the average drug shortage in 2025 had lasted 5.3 years, exceeding the 4.3 years seen in 2024
Drug shortages spark 'serious risk' as painkillers and antibiotics running low
